CytomX Therapeutics (CTMX) EBIAT: 2014-2025
Historic EBIAT for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -$14.2 million.
- CytomX Therapeutics' EBIAT fell 348.06% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 102.59%. This contributed to the annual value of $31.9 million for FY2024, which is 5700.88% up from last year.
- According to the latest figures from Q3 2025, CytomX Therapeutics' EBIAT is -$14.2 million, which was down 9,139.61% from -$154,000 recorded in Q2 2025.
- CytomX Therapeutics' EBIAT's 5-year high stood at $23.5 million during Q1 2025, with a 5-year trough of -$34.8 million in Q4 2021.
- For the 3-year period, CytomX Therapeutics' EBIAT averaged around $3.7 million, with its median value being $837,000 (2023).
- Examining YoY changes over the last 5 years, CytomX Therapeutics' EBIAT showed a top increase of 2,155.20% in 2024 and a maximum decrease of 501.10% in 2024.
- Quarterly analysis of 5 years shows CytomX Therapeutics' EBIAT stood at -$34.8 million in 2021, then surged by 74.80% to -$8.8 million in 2022, then skyrocketed by 109.54% to $837,000 in 2023, then surged by 2,155.20% to $18.9 million in 2024, then plummeted by 348.06% to -$14.2 million in 2025.
- Its last three reported values are -$14.2 million in Q3 2025, -$154,000 for Q2 2025, and $23.5 million during Q1 2025.